15.12
15.12 (0.05%)
As of Sep 24, 2021
Jasper Therapeutics, Inc. [AMHC]
Source:
Company Overview
Jasper Therapeutics, Inc is a clinical-stage biotechnology companyfocused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), ChronicInducible Urticaria (“CIndU”) and Asthma.
| Country | United States |
| Headquarters | redwood city, california |
| Phone Number | 6505491400 |
| Industry | finance |
| CEO | Ronald Martell |
| Website | www.jaspertherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-76.2 |
| Net Income | $-71.3 |
| Net Cash | $-15.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -81.6% |
| Profit as % of Stockholder Equity | -115.6% |
Management Effectiveness
| Return on Equity | -115.6% |
| Return on Assets | -89.2% |
| Turnover Ratio | |
| EBITA | $-76.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $79.9 |
| Total Liabilities | $18.2 |
| Operating Cash Flow | $-62.6 |
| Investing Cash Flow | $-0.5 |
| Financing Cash Flow | $47.9 |
